Novel RAF/MEK inhibitor CH5126766/VS‐6766 has efficacy in combination with eribulin for the treatment of triple‐negative breast cancer-Reference-Cited by-同舟云学术

Novel RAF/MEK inhibitor CH5126766/VS‐6766 has efficacy in combination with eribulin for the treatment of triple‐negative breast cancer

Author:

Ono Hisako¹²³^ORCID,Horinaka Mano³^ORCID,Sukeno Mamiko³,Morita Mie³,Yasuda Shusuke³,Nishimoto Emi³,Konishi Eiichi⁴,Sakai Toshiyuki³

Affiliation:

1. Department of Molecular Diagnostics and Therapeutics Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan

2. Department of Endocrine and Breast Surgery Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan

3. Department of Drug Discovery Medicine Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan

4. Department of Surgical Pathology Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

Reference45 articles.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献